analytical methods raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-07 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Doillon started acting at age five, starring in Kung Fu Master directed by Agnès Varda. She has since worked with directors including Jean Pierre Améris, Jacques Doillon, Guillaume Canet, Abel Ferrara and Maïwenn.
Phrixotoxins are peptide toxins derived from the venom of the Chilean copper tarantula Phrixotrichus auratus, also named Paraphysa scrofa. Phrixotoxin-1 and -2 block A-type voltage-gated potassium channels; phrixotoxin-3 blocks voltage-gated sodium channels. Similar toxins are found in other species, for instance the Chilean rose tarantula.
=== Monoclonal antibodies targeting the CGRP molecule === Eptinezumab (ALD403) is approved for prevention of migraine. Fremanezumab (TEV-48125) is approved for prevention of migraine. Galcanezumab (LY2951742) is approved for prevention of migraine and cluster headaches.
Regional tectonic processes affected mainland Portugal's morphostructural units differently, producing relief variations that subdivide the territory into ten regional geomorphological units. These units were shaped by the differing regional impacts of Cenozoic tectonics, climatic asymmetries in the Paleogene, Neogene, and Quaternary, and varied lithological responses to tectonic activity and climatic variability. Continental Portugal is predominantly low-altitude, with over 70% of the territory lying below 400 m (1,300 ft) and less than 12% rising above 700 m (2,300 ft) of elevation. Its geography is structured by the Tagus River, which enters from Spain and flows into the Tagus Estuary, as 95% of areas exceeding 400 m (1,300 ft) are situated to the north of the river while the regions south of the Tagus, encompassing Alentejo and the Algarve, have 62% of the lands below 200 m (660 ft). The territory north of the Tagus is marked by mountains and plateaus incised by river valleys, whereas the south is distinguished by rolling plains. The Madeira archipelago comprises the islands of Madeira and Porto Santo, together with the Desertas and Savage Islands, all of which are of volcanic origin. Approximately one-third of Madeira Island lies above 1,000 metres (3,300 ft) in elevation, and its landscape is characterised by a dense network of deep valleys with slopes rising several hundred metres, as well as streams that originate in the island's centre and diverge towards the coast, sustained by abundant rainfall.
=== Solvent/detergent (S/D) inactivation === This process, developed by the New York Blood Center, is the most widely used viral inactivation method to date. It is predominantly used in the blood plasma industry, by over 50 organizations worldwide and by the American Red Cross. This process is only effective for viruses enveloped in a lipid coat, however. The detergents used in this method interrupt the interactions between the molecules in the virus's lipid coating. Most enveloped viruses cannot exist without their lipid coating so are destroyed when exposed to these detergents. Other viruses may not be destroyed but they are unable to reproduce rendering them non-infective. The solvent creates an environment in which the aggregation reaction between the lipid coat and the detergent happen more rapidly. The detergent typically used is Triton X-100. This process has many of the advantages of the "traditional" removal techniques. This process does not denature proteins, because the detergents only affect lipids and lipid derivatives. There is a 100% viral death achieved by this process and the equipment is relatively simple and easy to use. Equipment designed to purify post-virus inactivated material would be necessary to guard against contamination of subsequent process streams. S/D treatment utilizes readily available and relatively inexpensive reagents, but these reagents must be removed from the product prior to distribution which would require extra process steps.
Sources: en.wikipedia.org
Portal: Prelude - An unofficial prequel to Portal, set before the activation of GLaDOS when scientists used to watch over the test chambers and instruct the test subjects. Portal Reloaded - A mod atop Portal 2 that introduces the ability to place a third portal that sends the player-characters or objects through between the present and a future state of the same test chamber. Actions in the present state will alter the future, though manipulation of the future situation will not impact the present, allowing, for example, for one to bring a weighted cube set in the present from its position in the future, back through the time portal, and use that version of the cube in the present. Portal: Revolution - A mod build on Portal 2 by Second Face Software, in which the player controls an anonymous test subject in the destroyed Aperture Science laboratories. The player is tasked to repair a teleportation device. The mod is set in between the events of Portal and Portal 2. Portal Stories: Mel - A mod build on Portal 2, in which the player controls Mel, a female test subject who is named after a character that Valve had originally designed for Portal 2's cooperative mode. It is a fan-made mod that takes place after the events of Portal and before the events of Portal 2. Prospekt - A fan-made sequel to Half-Life: Opposing Force that follows its protagonist, U.S. Marine Adrian Shepherd, as he is sent to help Gordon Freeman during the "Nova Prospekt" segment of Half-Life 2.
The epiglottis is a flap of elastic cartilage attached to the entrance of the larynx. It is covered with a mucous membrane and there are taste buds on its lingual surface which faces into the mouth. Its laryngeal surface faces into the larynx. The epiglottis functions to guard the entrance of the glottis, the opening between the vocal folds. It is normally pointed upward during breathing with its underside functioning as part of the pharynx, but during swallowing, the epiglottis folds down to a more horizontal position, with its upper side functioning as part of the pharynx. In this manner it prevents food from going into the trachea and instead directs it to the esophagus, which is behind. During swallowing, the backward motion of the tongue forces the epiglottis over the glottis' opening to prevent any food that is being swallowed from entering the larynx which leads to the lungs; the larynx is also pulled upwards to assist this process. Stimulation of the larynx by ingested matter produces a strong cough reflex in order to protect the lungs.
The submarines were under orders to report sightings before attempting to attack, so Flying Fish waited until nightfall, then surfaced to radio in its report. Fifth Fleet commander Spruance was convinced that a major battle was at hand. After consulting with Nimitz at Pacific Fleet Headquarters in Hawaii, he ordered Rear Admiral Marc Mitscher, commander of the Fast Carrier Task Force (Task Force 58), who had sent two carrier task groups north to intercept aircraft reinforcements from Japan, to reform and move west of Saipan into the Philippine Sea. TF 52's battleships, cruisers and escort carrier groups were ordered to remain near Saipan to protect the invasion fleet and provide air support for the landings. Shortly before midnight on 18 June Nimitz radioed Spruance that a Japanese vessel had broken radio silence. The message intercepted was an apparent dispatch from Ozawa to his land-based air forces on Guam. Radio direction-finding placed the sender approximately 355 miles (571 km) west-southwest of TF 58. Mitscher considered whether the radio messages were a Japanese deception, as the Japanese were known to send a single vessel off to break radio silence, to mislead their adversaries about the actual location of the main force. Mitscher realized that there was a chance of a night surface encounter with Ozawa's forces. Arleigh Burke, Mitscher's chief of staff (a former destroyer squadron commander who had won several night battles in the Solomons), assumed that battle line commander Willis Lee would welcome the opportunity. But Lee strongly opposed such an encounter.
== Awards and honors == Tanzi has received numerous awards, including the two highest awards for Alzheimer's disease research: The Metlife Foundation Award for Medical Research in Alzheimer's Disease Award and The Potamkin Prize. He was included on the list of the "Harvard 100 Most Influential Alumni", and was chosen by the Geoffrey Beene Foundation as a “Rock Star of Science”. In 2015, he was named by Time to the Time 100 Most Influential People in the World list. In 2018, Tanzi was inducted into the Rhode Island Heritage Hall of Fame. He was also inducted into the Cranston Hall of Fame in 2000. Tanzi was awarded an honorary doctorate from The University of Rhode Island on May 17, 2015.
== Awards == Vincent du Vigneaud Award for Excellence in Peptide Science (2000) American Chemical Society's Ralph F. Hirschmann Award in Peptide Chemistry (2004) Bruce Merrifield Award (2005) Fellow of the American Association of Pharmaceutical Scientists (2006) Dan K. Richardson Entrepreneurship Program's 2011 Entrepreneur of the Year
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.